TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Stage IV Esophageal Cancer
Source: Esophageal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage IV Esophageal Cancer
At diagnosis, approximately 50% of patients with esophageal cancer have metastatic disease and are candidates for palliative therapy.[1]
Source links and citations
Treatment options for stage IV esophageal cancer include:
Chemoradiation therapy followed by surgery (for patients with stage IVA disease).
Source links and citations
Chemotherapy, which has provided partial responses for patients with metastatic distal esophageal adenocarcinomas.[2-4]
Adjuvant therapy for patients with completely resected (negative margins) esophageal adenocarcinoma, esophageal squamous cell carcinoma, or gastroesophageal junction cancer who had residual pathologic disease after concurrent chemoradiation therapy.[5]
Immunotherapy and chemoimmunotherapy for patients with previously untreated, unresectable, advanced or metastatic esophageal squamous cell carcinoma.[6-8]
Immunotherapy and chemoimmunotherapy for patients with previously untreated advanced or metastatic esophageal adenocarcinoma or gastroesophageal junction cancer.[8-10]
Immunotherapy for patients who relapse after one prior line of standard therapy.[11,12]
Source links and citations
Nivolumab and chemotherapy for patients with adenocarcinoma.[9]
Source links and citations
Endoscopic-placed stents to provide palliation of dysphagia.[15]
Source links and citations
Radiation therapy with or without intraluminal intubation and dilation.
Clinical trials evaluating single-agent or combination chemotherapy.
The treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced, inoperable, recurrent, or metastatic esophageal cancer has improved with the introduction of chemoimmunotherapy as front-line therapy and immunotherapy for patients who relapse following one prior line of chemotherapy. First-line chemoimmunotherapy can now be considered the standard of care for patients with advanced esophageal cancer of squamous or adenocarcinoma histology and programmed death-ligand 1 (PD-L1) expression (although the optimal cutoff still needs to be defined). For more information, see the Immunotherapy and Chemoimmunotherapy section.
Source links and citations
Publication references
Read the original reference and check its publication notices.
- PubMed 10390007 · Original source
- PubMed 10566606 · Original source
- PubMed 11386268 · Original source
- PubMed 11916548 · Original source
- PubMed 12007950 · Original source
- PubMed 16820062 · Original source
- PubMed 17004508 · Original source
- PubMed 31582355 · Original source
- PubMed 33026938 · Original source
- PubMed 33789008 · Original source
- PubMed 34102137 · Original source
- PubMed 34454674 · Original source
- PubMed 35030335 · Original source
- PubMed 35108470 · Original source
- PubMed 9212013 · Original source
Preserved source evidence · Not medical advice